Search Results 281-290 of 15209 for TNF
... TNF treatment, abatacept, alemtuzumab, IVIg, belimumab, tocilizumab, or eculizumab within 12 weeks prior to screening; For patients scheduled to receive ...
Received CD20 inhibitor, anti-tumor necrosis factor treatment, abatacept, alemtuzumab, any other experimental or biological therapy, intravenous ...
Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, anti-tumor necrosis factor CD137, or anti-cytotoxic T-lymphocyte-associated ...
Subjects being administered biologic treatments (eg, anti-tumor necrosis factor (TNF) or anti-integrin monoclonal antibodies), immunosuppressants, systemic ...
Tumor necrosis factor inhibitors within 12 weeks of screening; Leflunomide within 8 weeks of screening; Therapeutic pheresis within 4 weeks of Screening; Any ...
Effect of Anti-TNF Biologic Exposure During Pregnancy on Villitis of Unknown Etiology Diagnoses in Patients with Autoimmune Disease. Reprod Sci. 2024 Apr ...
Learn about these growths that form in or near nerves connecting to the spinal cord. Surgery is the most common treatment.
The purpose of this study is to evaluate children ≥ 1 year of age and adults with neurofibromatosis type 1 (NF1) and plexiform neurofibromas treated with the ...
... tumor necrosis factor (TNF)-α agents) ≤ 2 weeks prior to registration, or anticipation of need for systemic immunosuppressive medication during the course ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.